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New York, New York; Philadelphia, Pennsylvania; and Best, the NetherlandsOBJECTIVES The aim of this proof-of-principle study is to validate the accuracy of fusion imaging
for percutaneous transapical access (TA).
BACKGROUND Structural heart disease interventions, including TA, are commonly obtained under
ﬂuoroscopic guidance, which lacks important spatial information. Computed tomographic angiography
(CTA)-ﬂuoroscopy fusion imaging can provide the 3-dimensional information necessary for improved
accuracy in planning and guidance of these interventions.
METHODS Twenty consecutive patients scheduled for percutaneous left ventricular puncture and
device closure using CTA-ﬂuoroscopy fusion guidance were prospectively recruited. The HeartNavigator
software (Philips Healthcare, Best, the Netherlands) was used to landmark the left ventricular epicardium
for TA (planned puncture site [PPS]). The PPS landmark was compared with the position of the TA closure
device on post-procedure CTA (actual puncture site). The distance between the PPS and actual puncture
site was calculated from 2 ﬁxed reference points (left main ostium and mitral prosthesis center) in
3 planes (x, y, and z). The distance from the left anterior descending artery at the same z-plane was
also assessed. TA-related complications associated with fusion imaging were recorded.
RESULTS The median (interquartile range [IQR]) TA distance difference between the PPS and actual
puncture site from the referenced left main ostium and mitral prosthesis center was 5.00 mm (IQR: 1.98 to
12.64 mm) and 3.27 mm (IQR: 1.88 to 11.24 mm) in the x-plane, 4.48 mm (IQR: 1.98 to 13.08 mm) and
4.00 mm (IQR: 1.62 to 11.86 mm) in the y-plane, and 5.57 mm (IQR: 3.89 to 13.62 mm) and 4.96 mm (IQR:
1.92 to 11.76 mm) in the z-plane. The mean TA distance to the left anterior descending artery was 15.5 
7.8 mm and 22.7  13.7 mm in the x- and y-planes. No TA-related complications were identiﬁed, including
evidence of coronary artery laceration.
CONCLUSIONS With the use of CTA-ﬂuoroscopy fusion imaging to guide TA, the actual puncture site
can be approximated near the PPS. Moreover, fusion imaging can helpmaintain an adequate access distance
from the left anterior descending artery, thereby, potentially reducing TA-related complications. (J Am Coll
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PA B B R E V I A T I O N S
A N D A C R O N YM S
2D = 2-dimensional
3D = 3-dimensional
ADO = Amplatzer ductal
occluder
APS = actual puncture site
CTA = computed tomogra
angiography
IQR = interquartile range
LAD = left anterior descen
LV = left ventricle
oLMCA = ostium of the left
coronary artery
PPS = planned puncture si
PVL = paravalvular leak
TA = transapical access
VAL = center of mitral
valve prosthesis
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170ercutaneous transapical access (TA) is being obtained prior to the procedure. This study was
increasingly used for a multitude of structural
heart interventions. These interventions
include closure of ventricular septal defects,
left ventricular (LV) pseudoaneurysms, and para-
valvular leaks (PVL) and have been more recently
used to aid in transcatheter mitral valve-in-valve
implantation for degenerative bioprosthetic valves
(1–4). TA provides a direct approach to the aortic
valve and mitral valve apparatus and has been shown
to signiﬁcantly decrease procedural and ﬂuoroscopy
times for complex structural heart cases (1). To
maintain TA safety and procedural success, it is
important to direct the puncture away from lung
parenchyma, epicardial coronary arteries, and papil-
lary muscles and to align the entry with the intendedphy
ding
main
tecardiac defect (1,5,6).
TA has been most commonly obtained
under ﬂuoroscopic guidance. Nevertheless,
ﬂuoroscopy has poor characterization of
soft tissue or nonradiopaque structures and
provides only 2-dimensional (2D) pro-
jections of complex 3-dimensional (3D)
anatomy; ﬂuoroscopic images lack the
spatial information necessary for complex
interventional procedures. The integration
of computed tomography angiography
(CTA) with ﬂuoroscopy in the catheteri-
zation laboratory, also known as CTA-
ﬂuoroscopy fusion imaging, now provides
an alternative to conventional ﬂuoroscop-
ically guided catheterization (1,3,4,7–9).
Fusion imaging has the potential to
improve procedural efﬁcacy and safety,
while reducing radiation exposure, contrast
volume requirements, and procedural
duration (1). Importantly, it may providefor accurate TA planning and guidance. How-
ever, little data exists on the procedural outcomes
assisted by fusion imaging. The aim of this proof-
of-principle study is to validate the accuracy of TA
performed using CTA-ﬂuoroscopy fusion imaging
for structural heart interventions.
METHODS
Study population. Twenty consecutive patients
scheduled to undergo percutaneous LV puncture and
subsequent closure using CTA-ﬂuoroscopy fusion
guidance were prospectively recruited from June 1,
2011, to June 1, 2012 at Lenox Hill Heart and
Vascular Institute/North Shore Long Island Jewish
Health System. Immediate post-procedural CTA
was performed. Written informed consent wasapproved byNorth Shore/Long Island JewishHealth
System’s institutional review board. All procedures
were performed in a dedicated structural heart cath-
eterization laboratory under general anesthesia.
Computed tomographic angiography–ﬂuoroscopy
fusion. Patients underwent cardiac CTA (256-slice
iCT scanner, Philips Healthcare, Cleveland, Ohio)
using helical scan mode with multiphase acquisition
(16 phases, 6.25% RR interval increments) and
retrospective electrocardiographic-gating. Nonionic
contrast media injection of 60 to 90 ml at a rate of
5 to 6 ml/s was used, depending on patient size and
renal function. The timing between contrast injection
and the beginning of image acquisition was deter-
mined with the aim of peak contrast concentration in
the LV. In 2 patients with renal insufﬁciency
(glomerular ﬁltration rate#30ml/min), contrast was
not administered on post-CTA follow-up.
The HeartNavigator system (Philips Healthcare,
Best, the Netherlands) was the prototype pro-
prietary software used for CTA-ﬂuoroscopy fusion
imaging. Pre-procedural CTA slices during end-
diastole were 3D volume-rendered and automati-
cally segmented to identify the left atrium, LV, and
aorta. Segmentation of the coronary arteries, lungs,
and ribs was performed manually. The images were
then analyzed and a TA route determined such that
entry into the LV was aligned with the cardiac
defect and away from lung parenchyma, coronary
arteries, and papillary muscles. The true LV apex is
typically thin-walled and should be avoided; an
adjacent site was chosen for puncture. Landmarks
were placed accordingly for skin entry, epicardial left
ventricular entry or planned puncture site (PPS),
and the defect that required intervention (Figs. 1A
to 1D).
The patient’s position on the x-ray table was
adjusted to achieve the isocenter of the heart in 2
orthogonal ﬂuoroscopic views. The CT images were
then coregistered and overlaid onto live ﬂuoroscopy
by using either internal markers, such as a prosthetic
valve frame, in 2 different views performed 20 apart.
Volume-rendered 3D images of the heart were
replaced with an outlined view of the prosthetic valve
and/or pseudoaneurysm, depending on procedure.
Finally, 3D-rendered images and landmarks were
displayed with the same perspective as the x-ray
system and any rotations of the c-armwere congruent
with the CT. Only those patients were included in
the study in which these guidance landmarks were
followed during the procedure for LV puncture.
Technique of transapical access and closure. Fused
overlay imaging was used to guide needle entry
Figure 1. Fusion-Guided Percutaneous TA
Pre-procedural 2-dimensional computed tomographic angiography images are 3-dimensional volume-rendered and segmented using the
HeartNavigator (Philips Healthcare, Best, the Netherlands). The aorta and coronary arteries are identiﬁed in red, the left ventricle in purple,
and mechanical mitral prosthesis in green. Landmarks (yellow dots) are placed to identify skin entry (1); epicardial left ventricle entry, or
planned puncture site (2, white arrow); and the structural heart defect, a paravalvular leak (3), to be intervened upon in this patient. They are
placed in direct line with each other away from lung parenchyma, coronary arteries, and papillary muscles. Landmarks are placed in the axial
(A), coronal (B), and sagittal (C) views and translated onto a 3-dimensional volume-rendered image (D). Computed tomographic angiography
images are then coregistered and overlaid onto live ﬂuoroscopy-guiding percutaneous transapical access (TA) with a 21-gauge needle (E),
entry of sheath (F), and closure (G).
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171following the appropriate landmarks (1). A 21-gauge
micropuncture needle (CookMedical, Bloomington,
Indiana) was used for access. Entry was determined
by using live ﬂuoroscopy and injecting diluted
contrast into the LV (Fig. 1E). The procedure was
also monitored with transesophageal echocardiog-
raphy to assess for the presence and degree of pleural
and pericardial effusions. After establishing LV en-
try, an 0.018-inch guidewire was advanced through
the needle, and the needle was exchanged for a 5-F or
6-F radial sheath (Cook Medical) (Fig. 1F). If
necessary, the radial sheath was exchanged for
alternative sizes or delivery sheaths ranging from 6-F
to 12-F.
TA was closed using a 6/4-mm Amplatzer Duct
Occluder (ADO) (St. Jude Medical, Minneapolis,Minnesota); this is an “off-label” use (Fig. 1G).
Implantation of the closure device was performed
under ﬂuoroscopic guidance. The device was
introduced from the delivery sheath and the distal
disk of the device was opened into the LV cavity.
The device was pulled back and a small amount of
contrast was injected to identify the endocardial
surface. The device was released after the disk
conformed to the endocardial surface and there was
elongation of the device body in the myocardium
with systolic compression.
Data collection and analysis. TA distance difference
was evaluated by the difference between the PPS as
determined by the pre-CTA–ﬂuoroscopic fusion
landmark and the actual puncture site (APS) as
determined by the epicardial surface of the ADO on
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172the post-CTA. CTA image sets, both pre- and
post-procedure, were chosen from the same diastolic
phase of the cardiac cycle. In addition, to reduce
measurement uncertainty, index points of ﬁxed
cardiac structures were determined including the
ostium of left main coronary artery (oLMCA) and
the center of the mitral valve prosthesis (VAL).
These points were chosen because of their reliability
of measurement and their stability around or within
the heart.
ImageJ software (National Institutes of Health,
Bethesda, Maryland) was used to perform analysis.
Coordinates of pre-procedure landmarks that were
placed from the HeartNavigator software for
guidance were transcribed onto the pre-procedural
CTA using ImageJ. Distance measurements were
calculated by subtracting the coordinates from the
ﬁxed cardiac structure to both the PPS and APS in
3 planes, lateral (x), anteroposterior (y), and cra-
niocaudal (z) (Figs. 2A to 2D). All coordinatesFigure 2. Determination of Distance Measurements
Using the ImageJ software (National Institutes of Health, Bethesda, Mar
following: pre-procedural epicardial left ventricular entry determined fr
mitral valve prosthesis (A), ostium of the left main coronary artery (B), e
Minneapolis, Minnesota), or actual puncture site (C), and left anterior de
site or actual puncture site (D). Distances were calculated by subtractinwere conﬁrmed in the sagittal, coronal, and trans-
verse planes simultaneously. The following mea-
surements were obtained: distance of PPS to
oLMCA and PPS to center of VAL in pre-
procedural CTA and APS to oLMCA and APS
to center of VAL in post-procedural CTA. Addi-
tional measurements obtained were the distances
from the left anterior descending (LAD) artery to
the PPS and APS on their respective imaging
studies at the same z-plane. The distance in 2D
and 3D were calculated using the Pythagorean
theorem. A diagrammatic representation of the
measurements is shown in Figure 3.
Two independent readers, blinded to both the
patients and each other, performed measurements.
Readers were trained on the appropriate study soft-
ware and standardized measurements were per-
formed on index cases prior to initiation of the study.
The average of the 2 readers was calculated and used
to determine the distance difference between theyland), the coordinates in x-, y-, and z-planes were obtained for the
om fusion imaging or planned puncture site, the center base of the
picardial surface of the Amplatzer Ductal Occluder (St. Jude Medical,
scending artery at the same z-plane of either the planned puncture
g coordinates in each plane individually.
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173PPS and APS in each of the 3 planes to better esti-
mate the true distance.
Clinical endpoints. Historical control subjects, who
had LV puncture/closure attempted prior to fusion
imaging guidance, matched to age and sex were
collected and compared to assess differences in
success rates and clinical endpoints. Procedural data
such as contrast volume and ﬂuoroscopy time were
recorded for the entire procedure. Technical success
was deﬁned as successful TA with introduction of
a sheath into the LV and closure of the entry site as
described herein. Clinical endpoints chosen included
TA-related complications related to fusion imaging:
coronary artery laceration (particularly of the LAD);
hemothorax; pericardial effusion/tamponade; closure
device embolization/migration; pneumothorax; new
wall motion abnormality; bleeding with hemody-
namic compromise requiring surgical closure; or
death.
Statistics. Statistical analyses were performed using
SPSS statistical package (version 20, IBM SPSS
Inc., Chicago, Illinois). Continuous variables were
reported as mean  SD or as median (interquartile
range [IQR]) where appropriate. Unpaired Student
t test and z test were used for the comparison of
continuous, normally distributed variables and to
compare proportions between the study group and
historical control subjects, respectively. Kolmogorov-
Smirnov and Shapiro-Wilk tests were performed
to assess whether measurements were normallyFigure 3. Illustration of Distance Measurements on a 3D Volume-R
(A) Distance measurements were performed from ﬁxed cardiac structur
mitral valve prosthesis (VAL), to both the planned puncture site (PPS) an
and craniocaudal (z). Differences between these measurements were th
(B) Distance measurement from the LAD to the PPS and APS were ma
relation to the left anterior descending (LAD) artery was calculated. CTdistributed. Interobserver variability between readers
was assessed using the Bland-Altman method and
the Pearson rank correlation coefﬁcient with limits of
agreement reported. Statistical signiﬁcance was
deﬁned as p < 0.05.
RESULTS
Patient demographics are presented in Table 1.
Patients had a mean age of 70  12 years and body
surface area of 1.9  0.2 m2. All patients had a
mitral valve prosthesis that could be used for refer-
ence. The types of procedures performed that
required TA were mitral PVL closure in 70%
(n ¼ 14), mitral PVL closure and transcatheter
valve-in-valve implantation in 20% (n ¼ 4), LV
pseudoaneurysm closure in 5% (n ¼ 1), and aortic
PVL and Gerbode ventricular septal defect closure
in 5% (n ¼ 1).
The median TA distance between APS and PPS
in reference to the oLMCAwas 5.00 mm (IQR: 1.98
to 12.64 mm) in the x-plane, 4.48 mm (IQR: 1.98 to
13.08 mm) in the y-plane, and 5.57 mm (IQR: 3.89
to 13.62 mm) in the z-plane. In reference to the
VAL, the median TA distance between APS and
PPS was 3.27 mm (IQR: 1.88 to 11.24 mm) in the
x-plane, 4.00 mm (IQR: 1.62 to 11.86 mm) in the
y-plane, and 4.96 mm (IQR: 1.92 to 11.76 mm) in
the z-plane (Table 2). The median TA 3D distance
was 15.57 mm (IQR: 7.67 to 20.51 mm) andendered Cardiac CTA
es, ostium of the left main coronary artery (oLMCA) and center of the
d actual puncture site (APS) in 3 planes: lateral (x), anteroposterior (y),
en used to calculate transapical access 3-dimensional (3D) error.
de at the same z-plane. Transapical access 2-dimensional error in
A ¼ computed tomography angiography.
Table 2. TA Distance Between APS and PPS Using Fixed
Cardiac Structures
Difference Between Pre- and
Post-Procedural CTA
Median
Distance, mm
IQR
(25%–75%)
From oLMCA, n ¼ 20
x-plane 5.00 1.98–12.64
y-plane 4.48 1.98–13.08
z-plane 5.57 3.89–13.62
3-dimensional 15.57 7.67–20.51
From VAL, n ¼ 20
x-plane 3.27 1.88–11.24
y-plane 4.00 1.62–11.86
z-plane 4.96 1.92–11.76
3-dimensional 14.11 9.08–18.05
From LAD, n ¼ 18
x-plane 5.68 3.12–7.43
y-plane 5.20 2.57–11.82
2-dimensional 9.11 5.70–13.46
APS ¼ actual puncture site; CTA ¼ computed tomography angiography;
IQR ¼ interquartile range; LAD ¼ left anterior descending artery; oLMCA ¼
ostium of left main coronary artery; PPS ¼ planned puncture site; TA ¼
transapical access; VAL ¼ center of mitral valve prosthesis.
Table 1. Patient Demographics
Patient Population
(n [ 20)
Historical Control Subjects
Age/Sex Matched
(n [ 20) p Value
Age, yrs 70  12 71  10 0.72
Male 13 (65) 13 (65) 1.00
Body surface area, m2 1.9  0.2 1.8  0.2 0.03
Body mass index, kg/m2 28.4  6.2 25.1  3.9 0.05
Ejection fraction, % 51  10 57  10 0.06
Chronic renal insufﬁciency, GFR #60 ml/min 12 (60) 9 (45) 0.34
Pulmonary disease 2 (10) 3 (15) 0.63
Arrhythmia 14 (70) 14 (70) 1.00
Mitral valve prosthesis 1.00
Mechanical 6 (30) 6 (30)
Biological 14 (70) 14 (70)
Type of procedure performed
Mitral PVL closure 14 (70) 19 (95) 0.12
Mitral PVL closure þ valve-in-valve implantation 4 (20) d
Left ventricular pseudoaneurysm closure 1 (5) 1 (5)
Aortic PVL and Gerbode VSD closure 1 (5) d
Values are mean  SD or n (%). Dashes indicate that this type of procedure was not performed (n = 0, 0%).
GFR ¼ glomerular ﬁltration rate; PVL ¼ paravalvular leak; VSD ¼ ventricular septal defect.
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17414.11mm (IQR: 9.08 to 18.05 mm) to the oLMCA
and VAL, respectively. The median TA distance
between APS and PPS in reference to the LAD was
5.68 mm (IQR: 3.12 to 7.43 mm) in the x-plane
and 5.20 mm (IQR: 2.57 to 11.82 mm) in the
y-plane, with a median 2D distance of 9.11 mm
(IQR: 5.70 to 13.46 mm). The mean TA distance
to the LAD was 15.5  7.8 mm and 22.7 
13.7 mm in x- and y-planes.
Distances measured between each of the 3 ﬁxed
cardiac structures (oLMCA, VAL, and LAD) and
the PPS or APS by the 2 independent cardiac
readers are reported in Table 3. Mean difference
between the 2 readers is also shown, ranging from
0.54 mm to 2.88 mm. The maximum observed
mean difference between the readers was 2.88 mm
 0.48 mm, across all measurement in 3 planes.
Pearson correlation coefﬁcient (Table 3) and
Bland-Altman plots (Fig. 4) in reference to each
measurement revealed agreement between observers
with plots shown. The overall mean difference be-
tween Reader #1 and Reader #2 was small.
Clinical endpoints. Historical control subjects
matched to age and sex were similar in patient
demographics to study patients, except for signiﬁ-
cantly less body surface area (1.8  0.2 m2 vs. 1.9
 0.2 m2; p¼ 0.03) and body mass index (25.1 3.9
kg/m2 vs. 28.4  6.2 kg/m2; p ¼ 0.05). There wereno differences in procedural data, contrast volume
(32  19 cc vs. 41  54 cc; p ¼ 0.4) and ﬂuoroscopy
time (29.4  22 min vs. 35.2  21 min; p ¼ 0.4).
Technical success was similar between groups with
Table 3. Independent Readers’ Measurements of the Distances Between PPS and APS and Fixed Structures in Multiple Planes
Reader #1,
Mean ± SD, mm
Reader #2,
Mean ± SD, mm
Limits of Agreement,
Mean Difference
(± 2SD Range), mm
Pearson Correlation
Coefﬁcient
Pre-procedural
Distance of PPS from oLMCA, n ¼ 20
x-plane 77.95  13.63 78.72  13.43 0.77 (–1.91 to 3.46) 0.995*
y-plane 31.51  19.28 32.03  19.06 0.52 (4.53 to 3.49) 0.994*
z-plane 54.89  8.61 54.50  8.51 0.39 (2.25 to 1.47) 0.994*
Distance of PPS from VAL, n ¼ 20
x-plane 73.06  13.03 74.74  12.77 1.68 (–3.00 to 6.37) 0.983*
y-plane 46.03  17.28 47.98  17.51 1.95 (7.08 to 3.18) 0.989*
z-plane 20.83  10.82 20.79  11.11 0.05 (4.71 to 4.62) 0.977*
Distance of PPS from LAD, n ¼ 18
x-plane 16.07  7.36 16.21  7.59 0.13 (–2.08 to 2.35) 0.989*
y-plane 20.92  8.05 20.69  7.81 0.23 (1.73 to 1.27) 0.996*
Post-procedural
Distance of APS from oLMCA, n ¼ 20
x-plane 73.96  12.56 74.00  12.59 0.05 (–5.16 to 5.25) 0.977*
y-plane 31.20  21.14 31.39  20.99 0.19 (3.02 to 2.64) 0.998*
z-plane 53.28  12.07 54.77  11.35 1.49 (–11.77 to 14.75) 0.833*
Distance of APS from VAL, n ¼ 20
x-plane 69.17  12.28 70.46  12.91 1.29 (–5.33 to 7.91) 0.965*
y-plane 47.27  19.35 48.81  19.66 1.53 (7.25 to 4.18) 0.989*
z-plane 19.15  11.41 20.42  11.86 1.27 (–3.09 to 5.64) 0.982*
Distance of APS from LAD, n ¼ 18
x-plane 15.66  7.84 15.34  7.88 0.31 (5.06 to 4.43) 0.952*
y-plane 22.70  13.69 22.69  13.75 0.01 (2.39 to 2.37) 0.996*
*Correlation signiﬁcant at the 0.01 level (2-tailed).
Abbreviations as in Table 2.
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175100% of patients having successful TA. The study
patients had no evidence of coronary artery laceration
identiﬁed on immediate post-procedural CTA.
Furthermore, no other acute complications associ-
ated with percutaneous TA were recognized. His-
torical control subjects, however, had a higher
incidence of complications (20% vs. 0%; p ¼ 0.03).
Two patients developed pericardial effusions/
tamponade requiring drainage; 1 patient developed a
hemothorax requiring drainage; and 1 patient died,
intraprocedurally, in the setting of suprasystemic
pulmonary hypertension after developing pulseless
electrical activity after TA.
D I SCUSS ION
TA provides a direct approach to both the aortic
valve and mitral valve apparatus. Traditionally,
TA was limited to diagnostic procedures due toincreased rates of complications with larger sheath
sizes and anticoagulation required for intervention
(5,6,10,11). The use of ﬂuoroscopy alone has
limited the ability of the interventionalist to reliably
achieve a direct puncture at a safe distance from
lung and coronary arteries while also being in direct
line with the cardiac defect of interest, increasing
the risk of bleeding, pneumothorax, and coronary
laceration and decreasing the rates of procedural
success with increased procedural times. Improved
pre-procedural planning and intraprocedural guid-
ance, with the use of fusion imaging, provide an
alternative means to guide a more accurate and safe
TA (1).
The results of this study demonstrate that, with
the use of CTA-ﬂuoroscopy fusion imaging to guide
TA, the APS can be approximated near the intended
or planned puncture site, despite cardiac motion.
The planned and actual transapical puncture sites
Figure 4. Bland-Altman Plots of Readers’ Measurements
Bland-Altman plots of measurements from Reader #1 and Reader #2 between the PPS and APS from ﬁxed cardiac structures (oLMCA, VAL,
and LAD). Representative plots of the x-plane are shown with y- and z-planes as inserts where appropriate. Abbreviations as in Figure 3.
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176were within a median distance ranging from 3.27 mm
to 5.57 mm of each other, across all 3 planes (x, y,
and z). In addition, placement of landmarks on the
pre-procedural CTA and segmentation of the car-
diac structures including the coronary arteries, aided
in avoidance of the coronary vasculature.
The actual transapical puncture site was able to be
maintained at a safe distance away from the LAD,
mean distance of approximately 1 to 2 cm (x- and
y-planes). Due to the ability to label the coronary
arteries, the location of the LAD with respect to TA
was determined without the need for coronary
angiography. Although complications have been
well reported with the TA approach, the potential
for improved safety using fusion imaging guidance is
further supported with this study (1).Study limitations. Although attempts were made to
reduce uncertainty in measurement, there may exist
differences that could not be accounted for between
the pre- and post-procedural CTA. Changes in the
index point position due to respiration could affect
measurement. In addition, all pre-procedural CTA
were performed with an inspiratory breath-hold; for
TA, however, needle puncture was performed dur-
ing cessation of ventilation in order to deﬂate the
lung away from puncture site. Furthermore, small
differences in volume status, cardiac chamber size,
and ejection fraction between studies are difﬁcult to
assess and were not corrected for.
Current fusion imaging software also does not
provide for motion compensation, speciﬁcally cardiac
motion. The potential fusion of multiple cardiac
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177phases, true 4-dimensional overlay, may further
improve the accuracy of this technology. Two patients
did not receive contrast for the post-procedural CTA,
reducing the number of patients for whom the dis-
tance of the APS to the LAD could be assessed.
Additionally, the sample size was small. This may be
attributed to the less than optimal variance noted
between readers.
In addition, the study results may also be
operator-dependent, requiring operator experience
with both percutaneous TA and fusion imaging
technology. Over 50 transapical procedures had
been performed at our center prior to enrollment
in the study and may have contributed to the
technical results reported. Additional CT training
is required for the acquisition and evaluation of
structural heart patients and separate instruction is
necessary for the fusion imaging technology (12).
Nonetheless, with the automation of many stepsin the fusion software, the learning curve is not
steep.
CONCLUS IONS
CTA-ﬂuoroscopy fusion imaging is useful for the
guidance of TA with the ability to accurately
puncture the LV while maintaining an adequate
distance from the LAD, thereby, potentially
reducing TA-related complications. This work
should promote further study on the use of CTA-
ﬂuoroscopy fusion imaging technology to guide
complex structural heart interventions.
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